Cosmos Health Inc. (COSM)
| Market Cap | 23.76M +14.2% |
| Revenue (ttm) | 73.73M +33.8% |
| Net Income | -24.39M |
| EPS | -0.57 |
| Shares Out | 100.63M |
| PE Ratio | n/a |
| Forward PE | 6.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,129,982 |
| Open | 0.2090 |
| Previous Close | 0.1978 |
| Day's Range | 0.2052 - 0.2392 |
| 52-Week Range | 0.1616 - 0.7700 |
| Beta | 4.44 |
| Analysts | n/a |
| Price Target | 2.95 (+1,149.47%) |
| Est. Earnings | Nov 24, 2026 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), N... [Read more]
Financial Performance
In 2025, Cosmos Health's revenue was $65.27 million, an increase of 19.93% compared to the previous year's $54.43 million. Losses were -$19.14 million, -14.45% less than in 2024.
Financial StatementsAnalyst Summary
The average 12-month stock price target for COSM is $2.95, which is an increase of 1,149.47% from the latest price.
News
Cosmos Health says U.S. monthly subscription value reaches $1.83M
Cosmos Health (COSM) announced that its U.S. direct-to-consumer subscription business reached $1,832,785 in monthly subscription value as of October 31, equivalent to approximately $22M on an annualiz...
CosmoFarm commissioning new automated order-processing infrastructure
Cosmos Health (COSM) announced that its wholly owned pharmaceutical distribution subsidiary, CosmoFarm, is commissioning new automated order-processing and vehicle-loading infrastructure at its distri...
Cosmos Health says U.S. active subscriptions surpass 12,000
Cosmos Health (COSM) launched its U.S. subscription model in mid-July 2026 and began scaling it in mid-September as it accelerated investment in its U.S. platform. On October 14, 2026, the…
Cosmos Health initiated with an Outperform at Noble Capital
Noble Capital initiated coverage of Cosmos Health (COSM) with an Outperform rating and $1.40 price target U.S. direct-to-consumer sales are gaining momentum, says the analyst, who believes Cosmos is p...
Cosmos Health expands e-commerce business to Australia, New Zealand
Cosmos Health (COSM) announced the expansion of its e-commerce and subscription business to Australia, New Zealand and the broader Oceania region. The business is now live across the region, and…
Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway
Now live in Oceania: e-commerce subscription business operating across Australia, New Zealand and the broader Oceania region, with sales already underway Attractive markets: together, Australia and Ne...
Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
Key Highlights Record revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record 2026 outlook reaffirmed: full-year revenue expect...
Cosmos Health expects Q4 revenue to reach $15M
Cosmos Health (COSM) announced that, based on its current growth trajectory, it expects U.S. revenue of approximately $15M for the fourth quarter of 2026, with gross profit of approximately $10.5M.
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days
● Q4 2026 U.S. revenue: approximately $15 million expected, based on the Company's current growth trajectory ● Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross...
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform ● 60.5% of U.S. online checkout orders ...
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date $902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-da...
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Record nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025 Nine-month 2026 revenue nearly matches the whole of 2024 - when full-y...
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics Proprie...
Cosmos Health’s CosmoFarm reaches annualized revenue above $60M
Cosmos Health (COSM) provided an update on its wholly owned pharmaceutical distribution subsidiary, CosmoFarm, which delivered record revenue of over $15M in the second quarter of 2026, representing a...
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal...
Cosmos’ contract manufacturing division surpasses $20M in implied revenue
Cosmos Health (COSM) announced that the contract manufacturing pipeline of its wholly owned subsidiary, Cana Laboratories, has surpassed $20M in implied revenue over the life of the underlying agreeme...
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreemen...
Cosmos Health secures five-year contract manufacturing agreement
Cosmos Health (COSM) announced that its wholly owned subsidiary, Cana Laboratories, has secured new five-year contract manufacturing agreements with Target Pharma totaling approximately 5.2M units. Th...
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today Secured orders for 1.04 mill...
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos Hea...
Cosmos Health secures five-year contract manufacturing agreement
Cosmos Health’s (COSM) Cana Laboratories secured a new five-year contract manufacturing agreement with Viofar covering approximately 2.5M units of ROSARTIA. The agreement represents approximately 500,...
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presenc...
Cosmos Health launches C-ScrubVet in the UK
Cosmos Health (COSM) has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet. C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial…
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and suppli...
Cosmos Health: A Company Transformed — 2026 Year-to-Date
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1...